Additionally, REV1 inhibition did not sensitize etoposide-treated cancer cells, suggesting that treatment modules that rely on DNA strand breaks to trigger cell death in cancer cells may not benefit from inhibiting REV1, unlike the significant potential of REV1 inhibition to sensitize cancer cells to chemotherapy treatment. The gene discussed is REV1; the disease is cancer.